Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ACETAMINOPHEN, ASPIRIN, AND CODEINE PHOSPHATE vs DI-METREX
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Acetaminophen: cyclooxygenase (COX) inhibitor, primarily central, analgesic and antipyretic. Aspirin: irreversible COX-1 and COX-2 inhibitor, analgesic, anti-inflammatory, antipyretic, antiplatelet. Codeine: prodrug converted to morphine; mu-opioid receptor agonist.
Combination of diphenhydramine (H1-antagonist) and pseudoephedrine (alpha-1 agonist). Diphenhydramine blocks histamine at H1 receptors, reducing allergic symptoms; pseudoephedrine causes vasoconstriction via alpha-1 adrenergic receptors, relieving nasal congestion.
Mild to moderate pain,Fever (acetaminophen and aspirin),Inflammatory conditions (aspirin)
Symptomatic relief of seasonal allergies,Upper respiratory tract allergies,Nasal congestion,Sinus congestion
1-2 tablets (each containing acetaminophen 300 mg, aspirin 300 mg, codeine phosphate 30 mg) orally every 4-6 hours as needed for pain; maximum 8 tablets/day.
4 mg orally once daily, increased to a maximum of 8 mg once daily if needed.
Acetaminophen: 2-3 hours (terminal). Aspirin: 15-30 minutes (parent drug); salicylate: 2-3 hours at low doses, 15-30 hours at high doses due to saturable metabolism. Codeine: 2.5-4 hours. Clinical context: Prolonged half-life of salicylate at high doses increases risk of toxicity; hepatic impairment prolongs acetaminophen and codeine half-lives.
The terminal elimination half-life is approximately 12 hours, requiring twice-daily dosing for steady-state concentrations.
Acetaminophen: hepatic via CYP2E1, CYP1A2, CYP3A4; glucuronidation and sulfation; NAPQI formation. Aspirin: hepatic hydrolysis to salicylate; conjugation with glycine and glucuronic acid. Codeine: hepatic via CYP2D6 to morphine (active); also via CYP3A4 to norcodeine.
Diphenhydramine: extensively metabolized via CYP2D6 to inactive metabolites; pseudoephedrine: partially metabolized in liver via N-demethylation to active metabolite (norpseudoephedrine) and excreted unchanged in urine.
Acetaminophen: renal excretion of metabolites (glucuronide and sulfate conjugates, ~85-90%), minor parent drug (<5%). Aspirin: renal excretion of salicylate and its metabolites (salicyluric acid, glucuronides, gentisic acid), dose-dependent; at therapeutic doses, ~50-80% as free salicylate and conjugates. Codeine: renal excretion of free and conjugated codeine (about 90%) and metabolites (morphine, norcodeine).
Renal excretion accounts for approximately 70% of elimination as unchanged drug and metabolites; biliary/fecal excretion accounts for the remaining 30%.
Acetaminophen: 10-25% (albumin). Aspirin: 50-80% (albumin), dose-dependent; salicylate: 75-90% (albumin). Codeine: ~7% (albumin).
Approximately 85% bound to serum albumin.
Acetaminophen: 0.9-1.0 L/kg (large distribution including liver). Aspirin: 0.15-0.2 L/kg (low Vd, confined to plasma and extracellular fluid); salicylate: 0.2-0.3 L/kg. Codeine: 3-6 L/kg (extensive tissue distribution). Clinical meaning: Large Vd for codeine suggests extensive tissue binding; aspirin Vd is small, consistent with limited extravascular distribution.
Vd is 0.8 L/kg, indicating distribution into total body water and some tissue binding.
Oral: Acetaminophen: 85-95%. Aspirin: 40-60% (due to first-pass hydrolysis to salicylate). Codeine: ~50% due to first-pass metabolism.
Oral bioavailability is 90% due to minimal first-pass metabolism.
GFR 30-59 m L/min: Administer every 6 hours; maximum 6 tablets/day. GFR 15-29 m L/min: Administer every 12 hours; maximum 4 tablets/day. GFR <15 m L/min: Not recommended due to accumulation of codeine metabolites.
GFR 30-50 m L/min: 2 mg once daily. GFR <30 m L/min: not recommended.
Child-Pugh Class A: No adjustment. Child-Pugh Class B: Reduce dose by 50% and extend interval to every 6 hours; maximum 4 tablets/day. Child-Pugh Class C: Contraindicated.
Child-Pugh A: no adjustment. Child-Pugh B: 2 mg once daily. Child-Pugh C: not recommended.
Not recommended for children <12 years due to aspirin risk of Reye syndrome. For children ≥12 years: Dose based on codeine component (0.5-1 mg/kg/dose) with maximum acetaminophen 75 mg/kg/day and aspirin 100 mg/kg/day. Typical: 1 tablet (acetaminophen 300 mg/aspirin 300 mg/codeine 30 mg) every 4-6 hours as needed; max 4 tablets/day.
Not established; contraindicated in children under 12 years.
Start with lowest effective dose (e.g., 1 tablet every 6 hours); monitor renal and hepatic function; maximum 6 tablets/day due to increased sensitivity and risk of adverse effects.
Start at 2 mg once daily; titrate cautiously due to increased risk of hypotension and cognitive effects.
Risk of medication errors: confusion between different strengths and concentrations of acetaminophen can result in accidental overdose and fatal hepatotoxicity. Aspirin use in children and teenagers with viral infections is associated with Reye's syndrome.
Not applicable (no FDA boxed warning).
Hepatotoxicity (acetaminophen dose >4 g/day), Reye's syndrome (aspirin in children), respiratory depression (codeine), tolerance/dependence, bleeding risk (aspirin), GI toxicity, renal impairment, hypersensitivity reactions.
Do not use in patients with severe hypertension or coronary artery disease; caution in hyperthyroidism, diabetes, glaucoma, prostatic hypertrophy, and MAOI use; avoid exceeding recommended dose due to risk of serious cardiovascular events; may cause drowsiness or excitability in children.
Hypersensitivity to any component, active peptic ulcer disease, bleeding disorders, severe hepatic impairment, severe respiratory depression, children with viral illness (aspirin), pregnancy (third trimester for aspirin, codeine cautious).
Hypersensitivity to diphenhydramine, pseudoephedrine, or any component; severe hypertension; severe coronary artery disease; concurrent MAOI therapy or within 14 days; narrow-angle glaucoma; urinary retention; during or within 2 weeks of MAOI use.
Avoid alcohol due to increased risk of acetaminophen hepatotoxicity and aspirin-induced GI bleeding. Avoid large amounts of caffeine or high-tyramine foods (e.g., aged cheeses, cured meats) as they may affect CYP2D6 metabolism of codeine.
Avoid alcohol entirely. Folic acid supplementation is often prescribed to reduce side effects; do not take any other folate supplements without approval. Caffeine may slightly increase absorption, but no specific dietary restrictions. Maintain adequate hydration to help prevent kidney toxicity.
Acetaminophen: Generally considered low risk; association with ASD and ADHD with prolonged use not fully established. Aspirin: First trimester: possible increased risk of gastroschisis; second trimester: relatively safe; third trimester: risk of premature closure of ductus arteriosus, oligohydramnios, and increased peripartum hemorrhage. Codeine: First trimester: possible neural tube defects; second and third trimesters: risk of respiratory depression, withdrawal in neonate with chronic use; neonatal opioid withdrawal syndrome (NOWS) possible.
DI-METREX (metformin) is classified as FDA Pregnancy Category B. First trimester: No increased risk of major congenital anomalies observed in human studies; some studies suggest reduced risk of neural tube defects in women with PCOS. Second and third trimesters: Risk of neonatal hypoglycemia and macrosomia reduced compared to untreated diabetes; no evidence of teratogenicity. Overall, benefits of glycemic control outweigh potential risks.
Acetaminophen: M/P ratio approximately 0.91-1.42; considered safe. Aspirin: M/P ratio 0.08-0.15; high doses may cause Reye's syndrome; avoid or use low doses. Codeine: M/P ratio about 2.5; variable metabolism; risk of CNS depression in infant; avoid due to potential for toxicity in CYP2D6 ultrarapid metabolizers.
Metformin is excreted into breast milk in small amounts with an M/P ratio (milk-to-plasma ratio) of approximately 0.35. Infant exposure is estimated at 0.2-1% of maternal weight-adjusted dose. No adverse effects reported in breastfed infants; however, caution in premature infants or those with renal impairment.
Acetaminophen: No dose adjustment needed. Aspirin: Avoid in third trimester; use lowest effective dose if necessary. Codeine: Avoid in pregnancy; if used, lowest effective dose for shortest duration; caution for CYP2D6 polymorphism. Pharmacokinetic changes: Increased clearance of codeine during pregnancy may require higher doses but risk outweighs benefit.
No routine dose adjustment recommended. However, as pregnancy progresses, renal function decreases and volume of distribution increases, which may reduce metformin clearance. Dose should be titrated to glycemic targets, up to a maximum of 2500 mg/day in divided doses. Monitor renal function and consider dose reduction if e GFR < 30 m L/min/1.73 m².
Combination analgesic with acetaminophen (hepatotoxic at high doses), aspirin (antiplatelet, GI irritant, contraindicated in children <12 due to Reye's syndrome), and codeine (prodrug to morphine via CYP2D6; efficacy depends on CYP2D6 phenotype; risk of CNS/respiratory depression). Avoid in severe hepatic/renal impairment, active peptic ulcer, bleeding disorders, or concomitant use of other CNS depressants. Maximum acetaminophen dose from all sources: 4 g/day.
DI-METREX (methotrexate) has a long half-life; monitor for cumulative toxicity. Administer folic acid supplementation to reduce gastrointestinal and hematologic side effects. Use with caution in patients with ascites or pleural effusions, as drug accumulation can occur. Premedication with NSAIDs increases methotrexate toxicity. Always check liver function tests and renal function before each dose.
Do not exceed recommended dose; acetaminophen overdosage can cause serious liver damage.,Do not take with other products containing acetaminophen or aspirin.,Avoid alcohol while taking this medication to reduce risk of liver toxicity and GI bleeding.,This product contains aspirin; do not give to children/teenagers with chickenpox or flu-like symptoms to avoid Reye's syndrome.,May cause drowsiness; do not drive or operate machinery until you know how you react.,Codeine is a narcotic pain reliever with abuse potential; use exactly as prescribed.,Seek medical attention if you experience signs of allergic reaction (rash, difficulty breathing) or bleeding (black/tarry stools, unusual bruising).
Take methotrexate exactly as prescribed, usually once weekly, not daily. Serious harm can occur if taken daily.,Avoid alcohol completely to reduce liver damage risk.,Report any unusual bleeding, bruising, fever, mouth sores, or persistent cough immediately.,Do not take any other medications, including over-the-counter and herbal products, without first consulting your doctor.,Use effective contraception; methotrexate can cause severe birth defects.
"Pirenzepine, a selective M1 muscarinic antagonist, reduces gastrointestinal motility and secretions, while codeine, an opioid agonist, also decreases gastrointestinal motility via mu-opioid receptors. Concurrent use leads to additive anticholinergic and opioid effects, resulting in enhanced risk of severe constipation, paralytic ileus, and central nervous system depression. Clinically, patients may experience exacerbated sedation, respiratory depression, and urinary retention."
"Ropinirole, a non-ergoline dopamine agonist used in Parkinson's disease and restless legs syndrome, may reduce the analgesic efficacy of codeine. This is likely due to pharmacodynamic antagonism at central dopamine and opioid receptors, as well as potential pharmacokinetic interactions that decrease the conversion of codeine to its active metabolite morphine via CYP2D6 inhibition by ropinirole. The resultant blunted opioid response can lead to inadequate pain control, necessitating dose adjustment or alternative therapy."
"Vemurafenib induces CYP3A4, significantly reducing the plasma concentrations of codeine, which is metabolized via CYP3A4 to its active metabolite morphine. This may diminish codeine's analgesic efficacy, potentially leading to inadequate pain control. Additionally, reduced formation of morphine may lower the risk of opioid-related adverse effects."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ACETAMINOPHEN, ASPIRIN, AND CODEINE PHOSPHATE vs DI-METREX, answered by our medical review team.
ACETAMINOPHEN, ASPIRIN, AND CODEINE PHOSPHATE is a Opioid Agonist that works by Acetaminophen: cyclooxygenase (COX) inhibitor, primarily central, analgesic and antipyretic. Aspirin: irreversible COX-1 and COX-2 inhibitor, analgesic, anti-inflammatory, antipyretic, antiplatelet. Codeine: prodrug converted to morphine; mu-opioid receptor agonist.. DI-METREX is a Antihistamine-Decongestant that works by Combination of diphenhydramine (H1-antagonist) and pseudoephedrine (alpha-1 agonist). Diphenhydramine blocks histamine at H1 receptors, reducing allergic symptoms; pseudoephedrine causes vasoconstriction via alpha-1 adrenergic receptors, relieving nasal congestion.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ACETAMINOPHEN, ASPIRIN, AND CODEINE PHOSPHATE and DI-METREX depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ACETAMINOPHEN, ASPIRIN, AND CODEINE PHOSPHATE is: 1-2 tablets (each containing acetaminophen 300 mg, aspirin 300 mg, codeine phosphate 30 mg) orally every 4-6 hours as needed for pain; maximum 8 tablets/day.. The standard adult dose of DI-METREX is: 4 mg orally once daily, increased to a maximum of 8 mg once daily if needed.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ACETAMINOPHEN, ASPIRIN, AND CODEINE PHOSPHATE and DI-METREX in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ACETAMINOPHEN, ASPIRIN, AND CODEINE PHOSPHATE is classified as Category D/X. Acetaminophen: Generally considered low risk; association with ASD and ADHD with prolonged use not fully established. Aspirin: First trimester: possible increased risk of gastrosch. DI-METREX is classified as Category C. DI-METREX (metformin) is classified as FDA Pregnancy Category B. First trimester: No increased risk of major congenital anomalies observed in human studies; some studies suggest re. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.